Aspire Biopharma Holdings, Inc. — Form 8-K
Filed September 9, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Aspire Biopharma Holdings, Inc. changed its legal name to Aspire-Lakewood Holdings, Inc. (effective September 9, 2026) and the Board authorized a $10 million share repurchase program. The authorization reflects confidence following the acquisition of Dura Control Systems Corp. (DCSC), which generated $209.5M revenue and $22.3M Adjusted EBITDA in 2025, and $103.9M revenue with $10.5M Adjusted EBITDA in the first half of 2026. The company has approximately 1.5 million shares outstanding; at current metrics, the $10M buyback represents ~58% of market cap.
Why this rating
DCSC acquisition materially transforms company from biotech to industrial holding; $10M buyback is massive relative to $17.4M market cap. Highly significant for this small-cap entity.
Tradability signal
NO TRADE
No trade: price $0.01 is below our $0.5 floor — spreads at this level eat any edge.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $0.01 | +10 min · unknown $0.01 ▲ 0.00% | +30 min · unknown $0.01 ▲ 0.00% | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.